Efficacy and Safety of Lapatinib Treatment in Trastuzumab Pretreated Patients with HER2 Positive Metastatic Breast Cancer - An Analysis of IntERB Registry in the Czech Republic

被引：0
|
作者：
Grell, P. [1 ]
Kandrnal, V. [2 ]
Bortlicek, Z. [2 ]
Vyzula, R. [1 ]
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S94 / S95
页数：2
相关论文
共 50 条
  • [41] Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
    Aye, T. T.
    Mon, S.
    Khine, M.
    Sein, N.
    Thant, N. M.
    Win, A. K.
    Aung, E. P. P.
    Hnin, P. T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A PHASE 2 STUDY OF TRASTUZUMAB EMTANSINE IN JAPANESE PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER
    Takahashi, S.
    Kashiwaba, M.
    Takao, S.
    Ito, Y.
    Doihara, H.
    Rai, Y.
    Matsubara, M.
    Kanatani, K.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 20 - 20
  • [44] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
  • [45] Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Bighin, Claudia
    Pronzato, Paolo
    Del Mastro, Lucia
    FUTURE ONCOLOGY, 2013, 9 (07) : 955 - 957
  • [46] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [47] Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
    von Minckwitz, G.
    Ponomarova, O.
    Morales, S.
    Zhang, N.
    Hanes, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [49] SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCER
    Sakaguchi, Haruna
    Ishihara, Mikiya
    Sawaki, Akihiko
    Nagaharu, Keiki
    Oda, Hiroyasu
    Sugawara, Yumiko
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [50] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
12345